Immune checkpoint inhibitors(ICI)have been rapidly extended their indication in various cancer types. On the other hand, immune-related adverse event(irAE)is observed in some cases and sometime causes fatal outcome. Enterocolitis is one of the major irAE, especially in the case treated with anti-CTLA-4 antibody. Although the combination therapy ofanti -CTLA-4 antibody and anti-PD-1 antibody has shown clinical benefit in some cancer types, a risk of enterocolitis is higher than monotherapy. Accumulated evidence has revealed the clinical features of enterocolitis caused by anti-CTLA-4 antibody and anti- PD-1/PD-L1 antibody. We summarize recent knowledge and discuss future perspectives.
|Number of pages||5|
|Journal||Gan to kagaku ryoho. Cancer & chemotherapy|
|Publication status||Published - 2020 Feb 1|
ASJC Scopus subject areas
- Cancer Research